King's College London

Research portal

Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: A population-based case-control study

Research output: Contribution to journalArticle

Standard

Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer : A population-based case-control study. / Lin, E.; Garmo, Hans; Van Hemelrijck, Mieke; Adolfsson, Jan; Stattin, Pär; Zethelius, Björn; Crawley, Danielle.

In: BMC Cancer, Vol. 20, No. 1, 551, 15.06.2020.

Research output: Contribution to journalArticle

Harvard

Lin, E, Garmo, H, Van Hemelrijck, M, Adolfsson, J, Stattin, P, Zethelius, B & Crawley, D 2020, 'Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: A population-based case-control study', BMC Cancer, vol. 20, no. 1, 551. https://doi.org/10.1186/s12885-020-07036-4

APA

Lin, E., Garmo, H., Van Hemelrijck, M., Adolfsson, J., Stattin, P., Zethelius, B., & Crawley, D. (2020). Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: A population-based case-control study. BMC Cancer, 20(1), [551]. https://doi.org/10.1186/s12885-020-07036-4

Vancouver

Lin E, Garmo H, Van Hemelrijck M, Adolfsson J, Stattin P, Zethelius B et al. Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: A population-based case-control study. BMC Cancer. 2020 Jun 15;20(1). 551. https://doi.org/10.1186/s12885-020-07036-4

Author

Lin, E. ; Garmo, Hans ; Van Hemelrijck, Mieke ; Adolfsson, Jan ; Stattin, Pär ; Zethelius, Björn ; Crawley, Danielle. / Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer : A population-based case-control study. In: BMC Cancer. 2020 ; Vol. 20, No. 1.

Bibtex Download

@article{60fcb392d5084a299a7d0de7024edee9,
title = "Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer: A population-based case-control study",
abstract = "Background: Prostate cancer (PCa) and type 2 diabetes mellitus (T2DM) are prevalent conditions that often occur concomitantly. However, many aspects of the impact of T2DM, particularly the duration of T2DM and antidiabetic medications, on PCa risk are poorly understood. Methods: To assess the association of duration of T2DM and antidiabetic medication with PCa risk, we designed a matched case-control study, including 31,415 men with PCa and 154,812 PCa-free men in Prostate Cancer data Base Sweden (PCBaSe) 4.1. Results: Overall, a decreased risk of PCa was observed for men with T2DM (odds ratio (OR): 0.81, 95% confidence interval (CI): 0.78-0.84), as compared to men without T2DM. The decreased risk of PCa was consistently showed across duration of T2DM. With respect to use of antidiabetic drugs, this inverse association with duration was also found for all medications types, as compared to men without T2DM, including insulin, metformin and sulphonylurea (SU) (e.g. 3- < 5 yr insulin OR:0.69, 95%CI:0.60-0.80; 3- < 5 yr metformin OR: 0.82, 95%CI: 0.74-0.91; 3- < 5 yr SU OR: 0.72, 95%CI: 0.62-0.83). When stratifying by PCa risk categories, this decreased risk was most evident for diagnosis of low and intermediate-risk PCa (low-risk OR: 0.65, 95%CI: 0.66-0.70, intermediate-risk OR: 0.80, 95%CI: 0.75-0.85). Conclusions: The study showed an inverse association between pre-existing T2DM and PCa across different durations of T2DM and all types of T2DM medication received. This inverse association was most evident for low- and intermediate-risk PCa, suggesting that whilst T2DM and its medication may protect some men from developing PCa, the relationship warrants further study.",
keywords = "Antidiabetic medication, Duration, Prostate cancer risk, Type 2 diabetes mellitus",
author = "E. Lin and Hans Garmo and {Van Hemelrijck}, Mieke and Jan Adolfsson and P{\"a}r Stattin and Bj{\"o}rn Zethelius and Danielle Crawley",
year = "2020",
month = jun,
day = "15",
doi = "10.1186/s12885-020-07036-4",
language = "English",
volume = "20",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",
number = "1",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Association of type 2 diabetes mellitus and antidiabetic medication with risk of prostate cancer

T2 - A population-based case-control study

AU - Lin, E.

AU - Garmo, Hans

AU - Van Hemelrijck, Mieke

AU - Adolfsson, Jan

AU - Stattin, Pär

AU - Zethelius, Björn

AU - Crawley, Danielle

PY - 2020/6/15

Y1 - 2020/6/15

N2 - Background: Prostate cancer (PCa) and type 2 diabetes mellitus (T2DM) are prevalent conditions that often occur concomitantly. However, many aspects of the impact of T2DM, particularly the duration of T2DM and antidiabetic medications, on PCa risk are poorly understood. Methods: To assess the association of duration of T2DM and antidiabetic medication with PCa risk, we designed a matched case-control study, including 31,415 men with PCa and 154,812 PCa-free men in Prostate Cancer data Base Sweden (PCBaSe) 4.1. Results: Overall, a decreased risk of PCa was observed for men with T2DM (odds ratio (OR): 0.81, 95% confidence interval (CI): 0.78-0.84), as compared to men without T2DM. The decreased risk of PCa was consistently showed across duration of T2DM. With respect to use of antidiabetic drugs, this inverse association with duration was also found for all medications types, as compared to men without T2DM, including insulin, metformin and sulphonylurea (SU) (e.g. 3- < 5 yr insulin OR:0.69, 95%CI:0.60-0.80; 3- < 5 yr metformin OR: 0.82, 95%CI: 0.74-0.91; 3- < 5 yr SU OR: 0.72, 95%CI: 0.62-0.83). When stratifying by PCa risk categories, this decreased risk was most evident for diagnosis of low and intermediate-risk PCa (low-risk OR: 0.65, 95%CI: 0.66-0.70, intermediate-risk OR: 0.80, 95%CI: 0.75-0.85). Conclusions: The study showed an inverse association between pre-existing T2DM and PCa across different durations of T2DM and all types of T2DM medication received. This inverse association was most evident for low- and intermediate-risk PCa, suggesting that whilst T2DM and its medication may protect some men from developing PCa, the relationship warrants further study.

AB - Background: Prostate cancer (PCa) and type 2 diabetes mellitus (T2DM) are prevalent conditions that often occur concomitantly. However, many aspects of the impact of T2DM, particularly the duration of T2DM and antidiabetic medications, on PCa risk are poorly understood. Methods: To assess the association of duration of T2DM and antidiabetic medication with PCa risk, we designed a matched case-control study, including 31,415 men with PCa and 154,812 PCa-free men in Prostate Cancer data Base Sweden (PCBaSe) 4.1. Results: Overall, a decreased risk of PCa was observed for men with T2DM (odds ratio (OR): 0.81, 95% confidence interval (CI): 0.78-0.84), as compared to men without T2DM. The decreased risk of PCa was consistently showed across duration of T2DM. With respect to use of antidiabetic drugs, this inverse association with duration was also found for all medications types, as compared to men without T2DM, including insulin, metformin and sulphonylurea (SU) (e.g. 3- < 5 yr insulin OR:0.69, 95%CI:0.60-0.80; 3- < 5 yr metformin OR: 0.82, 95%CI: 0.74-0.91; 3- < 5 yr SU OR: 0.72, 95%CI: 0.62-0.83). When stratifying by PCa risk categories, this decreased risk was most evident for diagnosis of low and intermediate-risk PCa (low-risk OR: 0.65, 95%CI: 0.66-0.70, intermediate-risk OR: 0.80, 95%CI: 0.75-0.85). Conclusions: The study showed an inverse association between pre-existing T2DM and PCa across different durations of T2DM and all types of T2DM medication received. This inverse association was most evident for low- and intermediate-risk PCa, suggesting that whilst T2DM and its medication may protect some men from developing PCa, the relationship warrants further study.

KW - Antidiabetic medication

KW - Duration

KW - Prostate cancer risk

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85086620769&partnerID=8YFLogxK

U2 - 10.1186/s12885-020-07036-4

DO - 10.1186/s12885-020-07036-4

M3 - Article

C2 - 32539807

AN - SCOPUS:85086620769

VL - 20

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

IS - 1

M1 - 551

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454